Form 4: TriSalus Life Sciences Director Receives Stock Units in Lieu of Cash Retainer
SEC Form 4 Filing
Director Liselotte Hyveled received 10,040 restricted stock units (RSUs) from TriSalus Life Sciences in place of her 2025 cash retainer for board service.
Summary
- Liselotte Hyveled, a director at TriSalus Life Sciences, received 10,040 restricted stock units (RSUs) on January 2, 2025.
- These RSUs were granted in lieu of her 2025 cash Annual Board Service Retainer, as per the Issuer's Non-Employee Director Compensation Policy.
- The RSUs will vest in equal quarterly installments on March 31, June 30, September 30, and December 31, 2025, contingent upon her continued service with the Issuer.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The director accepting stock in lieu of cash suggests confidence in the company's future, but it's a standard compensation practice.
Positives
- The director's decision to receive RSUs instead of cash demonstrates confidence in the company's future performance.
- The vesting schedule aligns the director's interests with the long-term success of the company.
Risks
- The value of the RSUs is subject to the volatility of TriSalus Life Sciences' stock price.
- The director must remain in service to receive the full benefit of the RSU award.
Future Outlook
The director's continued service is required for the RSUs to fully vest throughout 2025.
Industry Context
Granting stock-based compensation to directors is a common practice to align their interests with shareholders and incentivize long-term value creation. This is especially common in the biotech industry.
Comparison to Industry Standards
- Stock options and restricted stock units are frequently used in the biotech industry to compensate board members, aligning their interests with shareholders.
- Comparing the value of the 10,040 RSUs to the typical board compensation packages at similar-sized biotech companies would provide a benchmark for assessing the competitiveness of TriSalus's director compensation.
Stakeholder Impact
- Shareholders may view the director's acceptance of RSUs positively, as it aligns her interests with the company's long-term success.
- Employees may see this as a sign of confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 01/02/2025 | Date of the transaction where the director received the Restricted Stock Units |
| 01/06/2025 | Date of the signature on the SEC Form 4 filing |
| 03/31/2025 | First quarterly vesting date for the Restricted Stock Units |
| 06/30/2025 | Second quarterly vesting date for the Restricted Stock Units |
| 09/30/2025 | Third quarterly vesting date for the Restricted Stock Units |
| 12/31/2025 | Final quarterly vesting date for the Restricted Stock Units |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.